Rituximab and three dexamethasone cycles provide responses similar to splenectomy in women and those with immune thrombocytopenia of less than two years duration.

Rituximab and three dexamethasone cycles provide responses similar to splenectomy in women and those with immune thrombocytopenia of less than two years duration.

Item
http://www.wikidata.org/entity/Q33414722
A multicenter randomized open-label study of rituximab plus rhTPO vs rituximab in corticosteroid-resistant or relapsed ITP.A novel triple therapy for ITP using high-dose dexamethasone, low-dose rituximab, and cyclosporine (TT4).How we manage immune thrombocytopenia in the elderly.Gender and duration of disease differentiate responses to rituximab-dexamethasone therapy in adults with immune thrombocytopenia.Combination therapy in relapsed or refractory chronic immune thrombocytopenia: a case report and literature review.Balancing Therapy with Thrombopoietin Receptor Agonists and Splenectomy in Refractory Immune Thrombocytopenic Purpura: A Case of Postsplenectomy Thrombocytosis Requiring PlateletpheresisRituximab in immune thrombocytopenia: gender, age, and response as predictors of long-term response.Pathogenesis and Therapeutic Mechanisms in  Immune Thrombocytopenia (ITP)State of the art - how I manage immune thrombocytopenia.Efficacy and safety of eltrombopag in persistent and newly diagnosed ITP in clinical practice.Multi-center randomized open label phase II trial on three rituximab dosing schemes in immune thrombocytopenia patients.Treatment of Children with Persistent and Chronic Idiopathic Thrombocytopenic Purpura: 4 Infusions of Rituximab and Three 4-Day Cycles of Dexamethasone.Splenectomy for Immune Thrombocytopenia: Down but not out.Transitioning patients with immune thrombocytopenia to second-line therapy: Challenges and best practices.Eltrombopag-based combination treatment for immune thrombocytopenia
P2860

Rituximab and three dexamethasone cycles provide responses similar to splenectomy in women and those with immune thrombocytopenia of less than two years duration.

Item
http://www.wikidata.org/entity/Q33414722
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Rituximab and three dexamethas ...... less than two years duration.
@ast
Rituximab and three dexamethas ...... less than two years duration.
@en
type
label
Rituximab and three dexamethas ...... less than two years duration.
@ast
Rituximab and three dexamethas ...... less than two years duration.
@en
prefLabel
Rituximab and three dexamethas ...... less than two years duration.
@ast
Rituximab and three dexamethas ...... less than two years duration.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P698
P921
P932
P356
P1433
P1476
Rituximab and three dexamethas ...... less than two years duration.
@en
P2093
P2860
P304
P31
P356
10.3324/HAEMATOL.2013.103291
P433
P478
P50
P577
P698
P921
P932